Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy
Identifieur interne : 003318 ( Istex/Curation ); précédent : 003317; suivant : 003319Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy
Auteurs : Rascol [France] ; Kasia Sieradzan [Royaume-Uni] ; Hélène Peyro-Saint-Paul [France] ; Claire Thalamas [France] ; Christine Brefel-Courbon [France] ; Jean Michel Senard [France] ; Philippe Ladure [France] ; Jean Louis Montastruc [France] ; Andrew Lees [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-07.
English descriptors
Abstract
We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha‐2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.
Url:
DOI: 10.1002/mds.870130411
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003318
Links to Exploration step
ISTEX:15F0DC720320C512DF4B0A780CCBB502A45139EELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sieradzan, Kasia" sort="Sieradzan, Kasia" uniqKey="Sieradzan K" first="Kasia" last="Sieradzan">Kasia Sieradzan</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Manchester Royal Infirmary, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Manchester Royal Infirmary</wicri:regionArea></affiliation></author><author><name sortKey="Peyro Aint Aul, Helene" sort="Peyro Aint Aul, Helene" uniqKey="Peyro Aint Aul H" first="Hélène" last="Peyro-Saint-Paul">Hélène Peyro-Saint-Paul</name><affiliation wicri:level="1"><mods:affiliation>Institut de Recherche P. Fabre, Boulogne, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean Michel" last="Senard">Jean Michel Senard</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Ladure, Philippe" sort="Ladure, Philippe" uniqKey="Ladure P" first="Philippe" last="Ladure">Philippe Ladure</name><affiliation wicri:level="1"><mods:affiliation>Institut de Recherche P. Fabre, Boulogne, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:15F0DC720320C512DF4B0A780CCBB502A45139EE</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130411</idno><idno type="url">https://api.istex.fr/document/15F0DC720320C512DF4B0A780CCBB502A45139EE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003318</idno><idno type="wicri:Area/Istex/Curation">003318</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy</title><author><name sortKey="Rascol" sort="Rascol" uniqKey="Rascol" last="Rascol">Rascol</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sieradzan, Kasia" sort="Sieradzan, Kasia" uniqKey="Sieradzan K" first="Kasia" last="Sieradzan">Kasia Sieradzan</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Manchester Royal Infirmary, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurology, Manchester Royal Infirmary</wicri:regionArea></affiliation></author><author><name sortKey="Peyro Aint Aul, Helene" sort="Peyro Aint Aul, Helene" uniqKey="Peyro Aint Aul H" first="Hélène" last="Peyro-Saint-Paul">Hélène Peyro-Saint-Paul</name><affiliation wicri:level="1"><mods:affiliation>Institut de Recherche P. Fabre, Boulogne, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea></affiliation></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean Michel" last="Senard">Jean Michel Senard</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Ladure, Philippe" sort="Ladure, Philippe" uniqKey="Ladure P" first="Philippe" last="Ladure">Philippe Ladure</name><affiliation wicri:level="1"><mods:affiliation>Institut de Recherche P. Fabre, Boulogne, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherche P. Fabre, Boulogne</wicri:regionArea></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><affiliation wicri:level="1"><mods:affiliation>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, U.K.</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-07">1998-07</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="673">673</biblScope><biblScope unit="page" to="676">676</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">15F0DC720320C512DF4B0A780CCBB502A45139EE</idno><idno type="DOI">10.1002/mds.870130411</idno><idno type="ArticleID">MDS870130411</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alpha‐2 antagonist</term><term>Clinical trial</term><term>Efaroxan</term><term>Progressive supranuclear palsy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have tested, in a prospective randomized, double‐blind, placebo‐controlled, crossover, 12‐week study, the effects of 2 mg efaroxan, a potent alpha‐2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha‐2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003318 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 003318 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:15F0DC720320C512DF4B0A780CCBB502A45139EE
|texte= Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.23. |  |